drugset / Trial / NCT05281809
Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia
Phase 2
Recruiting
30 enrolled
John Lister
Allegheny Health Network · collabLentigen Technology, Inc. · collabMiltenyi Biotec, Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
This trial aims to demonstrate the feasibility of this approach to reliably generate product and to safely administer the product to patients who have B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia.
Timeline
- Start
- 2022-04-19
- Primary completion
- 2037-08-05
- Completion
- 2037-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Chimeric Antigen Receptor (CAR) T-Cell Product (Autologous) | Cell therapy | — | Intravenous |